Oncolytics Biotech Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters11-08

<a href="https://laohu8.com/S/ONCY">Oncolytics Biotech Inc</a> <onc.to> expected to post a loss of 10 cents a share - Earnings Preview </onc.to>

Oncolytics Biotech Inc ONC.TO is expected to show no change in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oncolytics Biotech Inc is $5.00, above its last closing price of $1.07.

Previous quarterly performance (using preferred earnings measure in Canadian dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jan. 1 0001	-0.10	-0.10	-0.10	Met	0.6
Mar. 31 0001	-0.11	-0.11	-0.09	Beat	16.3
Dec. 31 2023	-0.15	-0.15	-0.05	Beat	66.1
Sep. 30 2023	-0.10	-0.10	-0.14	Missed	-34.6
Jan. 1 0001		-0.11	-0.12	Missed	-6.3
Jan. 1 0001		-0.13	-0.10	Beat	24.5
Dec. 31 2022	-0.09	-0.10	-0.15	Missed	-54.7
Sep. 30 2022	-0.11	-0.11	-0.08	Beat	27.1

This summary was machine generated November 8 at 15:29 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481883774?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481883774","market":"us","top_or_hot":-1,"title":"Oncolytics Biotech Inc  expected to post a loss of 10 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ONCY\">Oncolytics Biotech Inc</a> <onc.to> expected to post a loss of 10 cents a share - Earnings Preview </onc.to></title></head><body><ul><li><p>Oncolytics Biotech Inc <span>ONC.TO</span>  is expected to show no change in quarterly revenue when it reports  results on November 11 (estimated) for the period ending September 30 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 10 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Oncolytics Biotech Inc is $5.00, above its last closing price of $1.07. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in Canadian dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td><p>-0.10</p></td><td><p>-0.10</p></td><td><p>-0.10</p></td><td><p>Met</p></td><td><p>0.6</p></td></tr><tr><td><p>Mar. 31 0001</p></td><td><p>-0.11</p></td><td><p>-0.11</p></td><td><p>-0.09</p></td><td><p>Beat</p></td><td><p>16.3</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-0.15</p></td><td><p>-0.15</p></td><td><p>-0.05</p></td><td><p>Beat</p></td><td><p>66.1</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-0.10</p></td><td><p>-0.10</p></td><td><p>-0.14</p></td><td><p>Missed</p></td><td><p>-34.6</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td></td><td><p>-0.11</p></td><td><p>-0.12</p></td><td><p>Missed</p></td><td><p>-6.3</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td></td><td><p>-0.13</p></td><td><p>-0.10</p></td><td><p>Beat</p></td><td><p>24.5</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td><p>-0.09</p></td><td><p>-0.10</p></td><td><p>-0.15</p></td><td><p>Missed</p></td><td><p>-54.7</p></td></tr><tr><td><p>Sep. 30 2022</p></td><td><p>-0.11</p></td><td><p>-0.11</p></td><td><p>-0.08</p></td><td><p>Beat</p></td><td><p>27.1</p></td></tr></tbody></table><p>This summary was machine generated November 8 at 15:29 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncolytics Biotech Inc  expected to post a loss of 10 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncolytics Biotech Inc  expected to post a loss of 10 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF1X1:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oncolytics Biotech Inc  expected to post a loss of 10 cents a share - Earnings Preview Oncolytics Biotech Inc ONC.TO  is expected to show no change in quarterly revenue when it reports  results on ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF1X1:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONCY","symbol_name":"Oncolytics Biotech Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF1X1:1","article_id":"2481883774","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481883774","pubTimestamp":1731079858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oncolytics Biotech Inc  expected to post a loss of10cents a share - Earnings Preview Oncolytics Biotech Inc ONC.TO  is expected to show no change in quarterly revenue when it reports  results on Novem","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ONCY":"Oncolytics Biotech Inc"},"translate_title":"Oncolytics Biotech Inc预计每股亏损10美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCY":0.9},"content_text":"Oncolytics Biotech Inc  expected to post a loss of 10 cents a share - Earnings Preview Oncolytics Biotech Inc ONC.TO  is expected to show no change in quarterly revenue when it reports  results on November 11 (estimated) for the period ending September 30 2024LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 10 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Oncolytics Biotech Inc is $5.00, above its last closing price of $1.07. Previous quarterly performance (using preferred earnings measure in Canadian dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jan. 1 0001-0.10-0.10-0.10Met0.6Mar. 31 0001-0.11-0.11-0.09Beat16.3Dec. 31 2023-0.15-0.15-0.05Beat66.1Sep. 30 2023-0.10-0.10-0.14Missed-34.6Jan. 1 0001-0.11-0.12Missed-6.3Jan. 1 0001-0.13-0.10Beat24.5Dec. 31 2022-0.09-0.10-0.15Missed-54.7Sep. 30 2022-0.11-0.11-0.08Beat27.1This summary was machine generated November 8 at 15:29 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481883774"}